Background: To compare the functional outcomes and retrograde ejaculation (RE) after transurethral incision of the prostate (TUIP) or silodosin in bladder outlet obstruction (BOO) secondary to a small prostate. Methods: Prospectively collected data from December 2011 through December 2014 of 192 LUTS patients having fertility concerns with prostate volume smaller than 40 ml receiving either TUIP or silodosin treatment were prospectively reviewed. The treatment outcomes were evaluated and compared. Results: TUIP was performed in 96 cases and silodosin 8 mg was prescribed in 96 cases. At 12 th months after TUIP or continuous silodosin treatment, the decrease in mean International Prostate Symptom Score (IPSS) and postvoiding residual urine (PVR) and the improvement of mean maximal flow rate (Q max ) were significant (p = 0.000). The improvement in IPPS and Qmax was significantly higher in TUIP group compared to silodosin group (p = 0.005, p = 0.000) with a lower rate of retrograde ejaculation (RE) in TUIP group. (11/96 vs 33/96) (p = 0.000) Conclusions: Both TUIP and silodosin ensures comparable improvement in PVR, IPSS and Q max with a lower rate of RE on the TUIP group in prostates weighing less than 40 grams suggesting that TUIP is a better choice in younger patiens seeking preservation of ejaculation with fertility concerns. KEY WORDS: Prostate; Retrograde ejaculation; Silodosin; Transurethral incision prostate.
SummaryNo conflict of interest declared. matic BPH; one blocks the α1-adrenoreceptors, the other inhibits the enzyme 5α-reductase. The former category is expected to provide relatively rapid symptom relief starting within 2-6 weeks (3). Silodosin, is an adrenergic blocker considered to be highly selective for α1a receptor subtype and confirmed to be highly effective in patients with BPH. However, almost 70% of patients report either anejaculation or hypospermia, with a concomitant orgasmic function (OF) impairment in 17% of the patients. Younger patients claimed higher rates of ejaculatory dysfunction (4). Transurethral resection of the prostate (TURP) is the gold standard for surgical treatment of BPH. Like many invasive modalities, this procedure is associated with with significant morbidity such as bleeding requiring blood transfusion (3%), and hyponatremia (TUR syndrome, 1%) as well as long-term complications such as stricture (7%), surgical revision (6%), significant urinary tract infection (4%), bleeding incontinence (3%), erectile dysfunction (10%), and ejaculatory dysfunction (65%) (5, 6). Furthermore, it may be an over-treatment for small size prostate in younger patients seeking protection of ejaculatory function. In this context, transurethral incision of the prostate (TUIP) became a an established treatment for BOO secondary to small-size BPH (7). TUIP has been reported to be an equivalent symptomatic improvement for men with prostate volume < 30 mL, with the advantages of less hemorrhage and less sexual dysfunction such as ED or RE than TURP (7,8). In the present study, our objective is t...